Does lapatinib work against HER2-negative breast cancers?

Ingrid A. Mayer, Carlos L. Arteaga

Research output: Contribution to journalComment/debate

14 Citations (Scopus)

Abstract

Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in hormone-dependent breast cancer cells and lead to escape from anti-estrogen therapy. Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.

Original languageEnglish (US)
Pages (from-to)1355-1357
Number of pages3
JournalClinical Cancer Research
Volume16
Issue number5
DOIs
StatePublished - Mar 1 2010

Fingerprint

Estrogen Receptors
Breast Neoplasms
Estrogens
Receptor Cross-Talk
Growth Factor Receptors
Hormones
Therapeutics
lapatinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Does lapatinib work against HER2-negative breast cancers? / Mayer, Ingrid A.; Arteaga, Carlos L.

In: Clinical Cancer Research, Vol. 16, No. 5, 01.03.2010, p. 1355-1357.

Research output: Contribution to journalComment/debate

@article{117ff6ae0991468d83fdde38510b88c5,
title = "Does lapatinib work against HER2-negative breast cancers?",
abstract = "Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in hormone-dependent breast cancer cells and lead to escape from anti-estrogen therapy. Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.",
author = "Mayer, {Ingrid A.} and Arteaga, {Carlos L.}",
year = "2010",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-09-3223",
language = "English (US)",
volume = "16",
pages = "1355--1357",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Does lapatinib work against HER2-negative breast cancers?

AU - Mayer, Ingrid A.

AU - Arteaga, Carlos L.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in hormone-dependent breast cancer cells and lead to escape from anti-estrogen therapy. Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.

AB - Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in hormone-dependent breast cancer cells and lead to escape from anti-estrogen therapy. Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.

UR - http://www.scopus.com/inward/record.url?scp=77649125821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649125821&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-3223

DO - 10.1158/1078-0432.CCR-09-3223

M3 - Comment/debate

VL - 16

SP - 1355

EP - 1357

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -